SAN DIEGO — Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading developer of insulin delivery and diabetes management technology, announced the appointment of Sandra Beaver to its Board of Directors, effective November 7, 2025. Beaver joins the board as an independent director and will serve on both the Audit Committee and the Cybersecurity and Data Oversight Committee.
“We welcome Sandra to our Board of Directors at this pivotal stage in Tandem’s evolution,” said John Sheridan, president and CEO of Tandem Diabetes Care. “Sandra is a dynamic finance executive whose experience and insight will be invaluable in helping guide our growth, particularly as we deliver transformative digital health solutions, scale efficiently, and expand into new markets and geographies.”
“I look forward to joining Tandem’s Board of Directors,” Beaver said. “As a global financial and healthcare leader, I see tremendous opportunity for Tandem to continue driving innovation and executing its strategy to create long-term, sustainable growth that benefits both the diabetes community and shareholders.”
Beaver brings more than two decades of global experience in strategic and operational finance across industries including healthcare, medical devices, gaming, enterprise technology, and manufacturing. She currently serves as Chief Financial Officer at Lyra Health, a leading provider of mental health solutions, where she oversees finance, accounting, investor relations, facilities, procurement, and corporate development.
Prior to joining Lyra Health in June 2025, Beaver was CFO at Evolus, a publicly traded medical aesthetics company, for three years. Earlier in her career, she held senior finance roles at Experian, a global data and technology company, and IGT, a worldwide gaming leader.
Beaver earned a Bachelor of Business Administration from the University of Massachusetts and holds a Professional Designation in Relational Database Design from UCLA.
